Published in Dement Geriatr Cogn Disord on January 08, 2001
Fluctuating cognition in dementia with Lewy bodies and Alzheimer's disease is qualitatively distinct. J Neurol Neurosurg Psychiatry (2004) 1.05
Assessment of cognition in mild cognitive impairment: a comparative study. Alzheimers Dement (2011) 1.00
Computerized neurocognitive testing and its potential for modern psychiatry. Psychiatry (Edgmont) (2004) 0.89
Dementia with Lewy bodies. Neurol Clin (2007) 0.83
Covariant perfusion patterns provide clues to the origin of cognitive fluctuations and attentional dysfunction in dementia with Lewy bodies. Int Psychogeriatr (2013) 0.82
Higher cortical deficits influence attentional processing in dementia with Lewy bodies, relative to patients with dementia of the Alzheimer's type and controls. J Neurol Neurosurg Psychiatry (2006) 0.81
Cortical-subcortical interactions in hypersomnia disorders: mechanisms underlying cognitive and behavioral aspects of the sleep-wake cycle. Front Neurol (2014) 0.79
Fluctuations in cognition and alertness vary independently in dementia with Lewy bodies. Mov Disord (2013) 0.78
Neurophysiological biomarkers for Lewy body dementias. Clin Neurophysiol (2015) 0.76
Assessing Fluctuating Cognition in Dementia Diagnosis: Interrater Reliability of the Clinician Assessment of Fluctuation. Am J Alzheimers Dis Other Demen (2015) 0.75
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 12.33
Geographical relation between Alzheimer's disease and aluminum in drinking water. Lancet (1989) 4.57
Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet (2000) 4.37
Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J (1978) 3.59
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Alzheimer's-disease-like changes in tau protein processing: association with aluminium accumulation in brains of renal dialysis patients. Lancet (1994) 2.74
A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. Neuroimage (2003) 2.67
Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry (1985) 2.47
Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol (2007) 2.47
Prevalence rates of dementia in an ageing population: are low rates due to the use of insensitive instruments? Age Ageing (1990) 2.45
D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics (1997) 2.28
Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci (1990) 2.24
Autism as a disorder of neural information processing: directions for research and targets for therapy. Mol Psychiatry (2004) 2.19
Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology (1999) 2.00
Necropsy evidence of central cholinergic deficits in senile dementia. Lancet (1977) 1.97
Drugs for Alzheimer's disease. BMJ (2001) 1.92
Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology (2000) 1.85
A rapid method for preparing synaptosomes: comparison, with alternative procedures. Brain Res (1981) 1.85
Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci (1977) 1.83
Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry (2006) 1.83
Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol (1978) 1.82
Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology (Berl) (1984) 1.79
Apolipoprotein E genes in Lewy body and Parkinson's disease. Lancet (1994) 1.77
Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology (2012) 1.67
The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia. Br J Psychiatry (2000) 1.61
Dementia with Lewy bodies and AD are not associated with occipital lobe atrophy on MRI. Neurology (2001) 1.59
Histochemical distribution of non-haem iron in the human brain. Acta Anat (Basel) (1992) 1.58
Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr (2001) 1.57
Risk factors in clinically diagnosed presenile dementia of the Alzheimer type: a case-control study in northern England. J Epidemiol Community Health (1995) 1.53
Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases. J Neurol Sci (1983) 1.51
Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med (1992) 1.49
Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain (1999) 1.48
Cognitive properties of sedation agents: comparison of the effects of nitrous oxide and midazolam on memory and mood. Br Dent J (1999) 1.45
Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Neuroimage (2002) 1.44
Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology (2002) 1.42
Smoking, nicotine and human performance. Pharmacol Ther (1983) 1.41
No evidence of an association between the T16189C mtDNA variant and late onset dementia. J Med Genet (2004) 1.40
Effect of a 915-MHz simulated mobile phone signal on cognitive function in man. Int J Radiat Biol (1999) 1.39
Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology (2004) 1.38
Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology (2007) 1.38
Effects of smoking on rapid information processing performance. Neuropsychobiology (1983) 1.38
School attendance as a factor in deliberate self poisoning by 12-15 year old adolescents. BMJ (1992) 1.38
Aluminosilicates and senile plaque formation in Alzheimer's disease. Lancet (1986) 1.35
Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology (2001) 1.34
Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology (2001) 1.32
Attention and fluctuating attention in patients with dementia with Lewy bodies and Alzheimer disease. Arch Neurol (2001) 1.32
The cholinergic hypothesis--ten years on. Br Med Bull (1986) 1.31
Cerebral injury during cardiopulmonary bypass: emboli impair memory. J Thorac Cardiovasc Surg (2001) 1.31
Cognitive performance in hypertensive and normotensive older subjects. Hypertension (2000) 1.31
Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol (2004) 1.30
Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm). Pharmacol Biochem Behav (2002) 1.28
Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies. Neurology (2005) 1.28
Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry (2002) 1.28
Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Significance for etiological theories of Alzheimer's disease. Am J Pathol (1994) 1.28
In-vitro inhibition of human erythrocyte acetylcholinesterase by salvia lavandulaefolia essential oil and constituent terpenes. J Pharm Pharmacol (2000) 1.28
Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (Lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties. Neuropsychopharmacology (2003) 1.28
Attentional deficits affect activities of daily living in dementia-associated with Parkinson's disease. J Neurol Neurosurg Psychiatry (2006) 1.27
Impaired attention predicts falling in Parkinson's disease. Parkinsonism Relat Disord (2008) 1.27
Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease. Ann N Y Acad Sci (1991) 1.24
Mitochondrial DNA haplogroups and susceptibility to AD and dementia with Lewy bodies. Neurology (2000) 1.22
Autonomic dysfunction in dementia. J Neurol Neurosurg Psychiatry (2006) 1.21
Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord (2002) 1.20
MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology (2000) 1.19
Anxiety, depression and psychosis in vascular dementia: prevalence and associations. J Affect Disord (2000) 1.18
Dementia with Lewy bodies. A distinct non-Alzheimer dementia syndrome? Brain Pathol (1998) 1.17
Medial temporal lobe atrophy on MRI in dementia with Lewy bodies. Neurology (1999) 1.16
Does the mitochondrial genome play a role in the etiology of Alzheimer's disease? Hum Genet (2006) 1.16
Clinically and neuropathologically distinct form of dementia in the elderly. Lancet (1989) 1.16
Extensive loss of choline acetyltransferase activity is not reflected by neuronal loss in the nucleus of Meynert in Alzheimer's disease. Neurosci Lett (1982) 1.14
Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease, and vascular dementia. Neurology (2000) 1.14
Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord (1993) 1.11
Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease. Br Med J (Clin Res Ed) (1981) 1.11
Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Respir Med (2006) 1.09
Poor attentional function predicts cognitive decline in patients with non-demented Parkinson's disease independent of motor phenotype. J Neurol Neurosurg Psychiatry (2008) 1.08
Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience (1995) 1.08
Molecular analysis of nicotinic receptor expression in autism. Brain Res Mol Brain Res (2004) 1.08
Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementia. Neuropathol Appl Neurobiol (2006) 1.08
Effect of 902 MHz mobile phone transmission on cognitive function in children. Bioelectromagnetics (2005) 1.08
In-vitro activity of S. lavandulaefolia (Spanish sage) relevant to treatment of Alzheimer's disease. J Pharm Pharmacol (2001) 1.07
Coenzyme A-acetylating enzymes in Alzheimer's disease: possible cholinergic 'compartment' of pyruvate dehydrogenase. Neurosci Lett (1980) 1.06
Cognitive performance in recreational users of MDMA of 'ecstasy': evidence for memory deficits. J Psychopharmacol (1998) 1.06